Ser91
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser91  -  HMGA1 iso2 (human)

Site Information
EEGIsQEssEEEQ__   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 452254

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 4 , 6 , 7 , 8 , 9 )
Disease tissue studied:
brain cancer ( 8 , 9 ) , glioblastoma ( 8 , 9 ) , glioma ( 8 , 9 ) , breast cancer ( 4 ) , prostate cancer ( 6 )
Relevant cell line - cell type - tissue:
293T (epithelial) ( 7 ) , breast ( 4 ) , M059K (glial) ( 8 , 9 ) , PC3 (prostate cell) ( 6 )

References 

1

Sgarra R, et al. (2009) Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J Proteome Res 8, 2978-89
19317492   Curated Info

2

Zhang Q, et al. (2007) A quantitative study on the in vitro and in vivo acetylation of high mobility group A1 proteins. J Am Soc Mass Spectrom 18, 1569-78
17627840   Curated Info

3

Zou Y, et al. (2007) A mass spectrometric study on the in vitro methylation of HMGA1a and HMGA1b proteins by PRMTs: methylation specificity, the effect of binding to AT-rich duplex DNA, and the effect of C-terminal phosphorylation. Biochemistry 46, 7896-906
17550233   Curated Info

4

Zou Y, Wang Y (2007) Mass spectrometric analysis of high-mobility group proteins and their post-translational modifications in normal and cancerous human breast tissues. J Proteome Res 6, 2304-14
17455969   Curated Info

5

Jiang X, Wang Y (2006) Acetylation and phosphorylation of high-mobility group A1 proteins in PC-3 human tumor cells. Biochemistry 45, 7194-201
16752910   Curated Info

6

Zou Y, Wang Y (2005) Tandem mass spectrometry for the examination of the posttranslational modifications of high-mobility group A1 proteins: symmetric and asymmetric dimethylation of Arg25 in HMGA1a protein. Biochemistry 44, 6293-301
15835918   Curated Info

7

Guo A (2004) CST Curation Set: 432; Year: 2004; Biosample/Treatment: cell line, 293T/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

8

Guo A (2004) CST Curation Set: 309; Year: 2004; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

9

Guo A (2004) CST Curation Set: 311; Year: 2004; Biosample/Treatment: cell line, M059K/etoposide; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info